Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

r parts of the body, has an especially poor prognosis, with a five-year survival rate of 27 percent. Currently, there are two and a half million breast cancer survivors in the United States. According to the ACS, breast cancer death rates are going down; the decline may be the result of early detection and treatment.

About the Study

Prior to study initiation, the Norton-Simon mathematical model (Norton et al, AACR 2005) -- which explores how the growth characteristics of a cancer affect response to chemotherapy -- was applied to determine that the maximum impact of Xeloda treatment in breast cancer patients occurs after seven days. Based on this finding, the single-center, open-label phase I/II trial was designed to determine the maximum tolerated dose (MTD) of Xeloda administered orally for seven days, followed by a seven-day rest (7-on/7-off), in patients with advanced-stage breast cancer. MTD was defined as the highest dose for which the incidence of dose-limiting toxicity (DLT) is less than 33 percent. DLT was defined as grade 3/4 hematologic toxicity lasting greater than two weeks despite growth factor support, or any grade 3/4 nonhematologic toxicity.

The Phase I study dose escalation scheme was a standard "3+3" design, using flat dosing that begins at 1,500 mg twice daily and increases by 500 mg/dose level until the MTD is reached. All patients in a cohort were observed for 28 days before enrollment to the next level is permitted to monitor for delayed toxicity.

The study showed that the dose dense regimen was well-tolerated in patients with advanced breast cancer, allowing safe delivery of higher daily doses than routinely used in practice. Of the 21 patients recruited for the trial, 18 were treated with Xeloda and reached a maximum tolerated dose of 2,000 mg twice daily. There were no grade 4/5 toxicities and grade 3 toxicities (which included one dose-limiting incident of hand-foot syndrome at 2,000 mg twice daily and two at 2,0
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CLEVELAND , May 22, 2013 /PRNewswire/ ... Software,s enterprise content management (ECM) ... Meditech,s Hospital Information System .  These organizations ... IT system and will use OnBase to ... corporate initiatives.   (Logo:  ...
(Date:5/22/2013)... 2013 Z-Medica, a leading developer and marketer ... first-ever line of products designed to meet the unique ... ® EMS 4x4 Dressing, QuikClot ® EMS ... Gauze™, all custom-designed to help responders stop bleeding fast ... to a hospital or trauma center. The line includes ...
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
Breaking Medicine Technology:Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
(Date:5/22/2013)... research shows that craving drugs such as nicotine ... brain that are implicated in determining the value ... Dr. Alain Dagher, from McGill University, suggests ... underlie addiction. These results were presented at the ... the Canadian Association for Neuroscience - Association Canadienne ...
(Date:5/22/2013)... (HealthDay News) -- Roughly four in 10 uninsured patients ... (COPD) actually do not have the lung disease, a ... were made based on an evaluation of symptoms, rather ... test known as spirometry, which shows how well a ... air they can exhale and how long that takes. ...
(Date:5/22/2013)... Mathews from the University of Melbourne said this small ... undoubted benefits from CT scans in diagnosing and monitoring ... British Medical Journal today and involved researchers ... the International Agency for Research on Cancer in Lyon, ... very useful in providing detailed three dimensional pictures to ...
(Date:5/22/2013)... King of Prussia, PA (PRWEB) May 22, 2013 ... is proud to announce its participation in the Greater Philadelphia ... experienced cyclists and recreational riders who are passionate about stopping ... affects more than 25 million Americans. , The Tour ... Ambler Campus, located at 580 Meetinghouse Road in Ambler, 30 ...
Breaking Medicine News(10 mins):Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3Health News:Addiction as a disorder of decision-making 2Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3
... tripled its customer,base in 2008 and now serves more ... part because of economic uncertainty. Vendormate captures,credentials, and ... chain,interruptions. , "With the global ... anxious about their supply chain," said Andy,Monin, Vendormate president ...
... Bureau Chief Lydia Parnes -PALO ALTO, Calif., Jan. 13 ... of legal services to technology, life sciences, and growth ... the firm as a new partner in March. The ... at the Federal Trade Commission (FTC), Parnes is a ...
... Study will begin recruiting volunteers to take part in its comprehensive study ... a briefing, NIH officials announced that the first phase of recruitment for ... York. , ... Washington, DC (PRWEB) January 13, 2009 ...
... BoxTone(R) Inc., the expert in mobile user management, today announced it ... new purchases of its market-leading software solution to manage, monitor and ... ... January 13, 2009 -- BoxTone(R) Inc., the expert in mobile user ...
... PRINCETON, N.J., Jan. 13 Medarex, Inc. (Nasdaq: ... of the company,s strong science-base and strategy for ... provided were recent highlights of Medarex,s record of ... outlook for product pipeline milestones in 2009, underscoring ...
... lost substantially fewer days of work and worked fewer ... the Feb. 1 issue of Clinical Infectious Diseases ... drug resistance among this year,s flu strains, the study ... The burden of influenza-like illnesses during the flu season ...
Cached Medicine News:Health News:Economic Uncertainty Fuels Vendormate Growth in 2008 2Health News:Wilson Sonsini Goodrich & Rosati Expands Consumer Regulatory Practice 2Health News:National Children's Study Begins Recruiting Volunteers 2Health News:National Children's Study Begins Recruiting Volunteers 3Health News:National Children's Study Begins Recruiting Volunteers 4Health News:National Children's Study Begins Recruiting Volunteers 5Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 2Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 3Health News:BoxTone Presents Mobile Industry with Timely Money Back Software Guarantee for Managing Enterprise BlackBerry Platform 4Health News:Medarex Reviews Recent Highlights and Outlook for 2009 2Health News:Medarex Reviews Recent Highlights and Outlook for 2009 3Health News:Study shows workplace benefits of influenza vaccination in 50-64 year olds 2
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in human serum....
Medicine Products: